Delayed HIV diagnosis in a cystic fibrosis patient: Not just another exacerbation

Sapna Bhatia a, Bernadette Jakeman b, Carolyn Cotton a, Keenan Ryan c, Husam Bader a, Elaine Thomas d, Theresa Heynekamp a, *

a Department of Internal Medicine, Division of Pulmonary Critical Care and Sleep Medicine, University of New Mexico Hospital, Albuquerque, NM, USA
b Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
c Department of Pharmacy, University of New Mexico Hospital, Albuquerque, NM, USA
d Department of Internal Medicine, Division of Infectious Diseases, University of New Mexico Hospital, Albuquerque, NM, 87106, USA

ARTICLE INFO

Keywords:
Cystic fibrosis
HIV
Pneumocystis pneumonia

ABSTRACT

Patients with cystic fibrosis (CF) are living longer due to advancements in treatment. We present a patient with CF in whom diagnoses of Human Immunodeficiency Virus (HIV) and severe pneumocystis pneumonia were delayed due to anchor bias. Our case highlights the importance of routine age-appropriate health screenings in patients with CF. In addition, we discuss the number of management challenges that may arise in patients with a dual diagnosis of CF and HIV.

1. Introduction

Patients with cystic fibrosis (CF) are living longer due to advances in care, with an average life expectancy of approximately 44 years [1]. Thus, it is important for CF providers not only to prevent disease progression and treat CF exacerbations, but also to consider age-appropriate health screening recommended for the general population. In patients with chronic illnesses, new or co-existing diagnoses may be missed due to anchor bias. Anchoring is a cognitive bias that may cause clinicians to focus too heavily on previously known information when making clinical decisions. We describe a case in which anchor bias (known CF diagnosis) delayed diagnosis and treatment of pneumocystis pneumonia (PCP) in a patient with undiagnosed HIV, resulting in adverse outcomes.

1.1. Case description

A 39-year-old man diagnosed in childhood with cystic fibrosis (genotype 3849 + 10 kb leading to a C to-T change, homozygous) had been followed at a CF specialty clinic but had significant gaps between visits. The patient presented with a three-day history of dyspnea, productive cough, fevers, and hypoxia. Prior to hospitalization patient was on as needed oxygen at night, but had increased to 2.5 lpm at home over the past three days. Chest radiograph showed new bilateral perihilar infiltrates and laboratory evaluation showed leukocytosis (14 × 10³ cells/µL). The patient had a history of colonization with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, chronic sinusitis, obesity, and gastric reflux disease. Patient did not have history of pancreatic insufficiency prior to hospitalization. Three months prior to hospitalization, pulmonary function tests were FVC 3.60L/76% predicted, FEV1 2.18L/57% predicted, FEV1/FVC 60/75% predicted, FEV1 25–75 30% predicted; oxygen saturation was 93% on room air. At that time patient was also diagnosed with thrush and tinea cruris. Prior to that visit there was a 3-year gap in care. At the time of hospitalization home medications included albuterol/ipratropium inhalation solution, azithromycin, docusate, dorame alfa, ergocalciferol, fluticasone/salmeterol inhalation powder, multivitamin, pantoprazole and tobramycin inhalation solution. The patient denied tobacco, alco-

* Corresponding author. Lovelace Medical Group, 500 Walter St NE, Suite 501, Albuquerque, NM, 87102, USA.
E-mail address: Theresa.heynekamp@lovelace.com (T. Heynekamp).

https://doi.org/10.1016/j.rmcr.2021.101545
Received 18 June 2021; Received in revised form 5 October 2021; Accepted 7 November 2021
Available online 9 November 2021
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
hol, or recreational/injection drug use. He was in a monogamous relationship with a female partner. The patient denied history of having sexual contact with men. The patient also had no history of blood transfusions. Patient did report that a former female partner died of an unknown illness several years prior to his hospitalization.

The patient was admitted to the hospital with a presumed diagnosis of CF exacerbation. Initially the patient received 5 lpm of oxygen and oxygen saturation was 94%. Intravenous cefepime, tobramycin, vancomycin and standard CF therapies were initiated. Infectious Diseases and Pulmonary services were consulted. Evaluations for causes of acute hypoxic respiratory failure included bacterial, fungal, and mycobacterial sputum cultures, mycoplasma and coccidioides serologies, screening for connective tissue disease, urine legionella antigen, urine pneumococcal antigen, and respiratory viral panel, all of which were unrevealing. An echocardiogram showed normal left ventricular systolic function (LVEF) with pulmonary artery pressure of 37 mmHg. The patient’s pulmonary condition worsened; on hospital day 4 he developed respiratory distress and sudden increase in oxygen requirement. A computed tomography (CT) scan of the chest with contrast showed extensive bilateral parenchymal ground glass opacities with peribronchial consolidation, read more as consistent with atypical pneumonia than with CF exacerbation, though pre-existing bronchiectasis made interpretation difficult. The patient was transferred to the intensive care unit (ICU) (see Fig. 1). On hospital day 5 a consultant suggested HIV testing, as well as a bronchoscopy, but the patient was initially unstable and the procedure was deferred. On hospital day 8, an HIV screen was positive and confirmed with Western blot; CD4⁺ cell count was 56 cells/μL and HIV viral load was 947,000 copies/mL. On hospital day 9, the patient underwent bronchoscopy; pneumocystis was identified by calcofluor stain from bronchoalveolar lavage. The patient was treated with sulfamethoxazole/trimethoprim 15mg/kg/day (based on trimethoprim component), prednisone taper, and antiretroviral therapy. The patient responded to treatment and did not require intubation; however, he developed a spontaneous pneumothorax, requiring multiple thoracostomy tubes (one with a Heimlich valve) and eventually was transferred to a specialty hospital for chemical pleurodesis. Screening tests for sexually transmitted diseases, tuberculosis, hepatitis, and toxoplasmosis were negative.

The patient is now followed by both the HIV and CF specialty clinics at our institution and he has remained stable with chronic oxygen requirement (2–3 LPM), improved CD4 cell count and an undetectable HIV viral load. No evidence of prior HIV screening was documented prior to hospitalization. His current female partner is not infected with HIV.

2. Discussion and conclusions

To our knowledge there are only two cases reported in the literature describing HIV infection in patients with CF [2,3]. Hoyer et al. [2] described a 39-year-old man with long-standing HIV, well controlled on ART, who was diagnosed with CF after being hospitalized several times for recurrent pneumonias, initially presumed to be due to his underlying immunocompromise. When BAL culture yielded non-mucoid and mucoid phenotypes of P. aeruginosa, a subsequent diagnosis of CF was made. Anchor bias in the case presented by Hoyer et al. delayed the diagnosis and treatment of CF. The authors concluded that the prevalence of CF in people with HIV (PWH) may be underestimated and should be suspected in a diagnosis of P. aeruginosa pneumonia.

Our case illustrates anchor bias in the reverse, where expert specialty providers presumed the patient’s condition was caused by CF, leading to delayed diagnosis and treatment of PCP and HIV. Because CF is a serious chronic condition that historically has had a short lifespan and where symptoms dominate patients’ health, CF patients like ours may not receive usual health screening, such as HIV testing. HIV screening had not been performed in this patient case prior to hospitalization, despite the United States Centers for Disease Control recommendation that all patients aged 13–64 years be screened [4]. Additionally, the patient would have been considered low-risk, not meeting criteria for indicator condition-guided HIV testing as outlined by European Centre for Disease Prevention and Control [5].

Fig. 1. CT scan showing extensive bilateral parenchymal ground glass opacities with peribronchial consolidation.
Table 1
Potential drug interactions to consider in patients with CF and HIV [24,25].

| Medications commonly used in patients with CF | Drug interaction with HIV antiretroviral medication |
|-----------------------------------------------|---------------------------------------------------|
| Vitamins containing divalent cations (e.g., iron, magnesium) | May decrease absorption of integrase strand transfer inhibitors (e.g., dolutegravir, raltegravir) |
| Corticosteroids, including inhaled formulations (e.g., fluticasone) | Antiretrovirals and antiretroviral boosting agents (e.g., ritonavir, cobicistat) may increase corticosteroid concentrations |
| Acid suppressant therapy (e.g., omeprazole) | May decrease concentrations of rilpivirine and atazanavir |
| Triazole antifungals (e.g., voriconazole) | Triazole concentrations may be increased or decreased and antivirals concentrations may be increased. |
| CFTR modulators (e.g., lumacaftor) | CFTR modulators may decrease concentrations of non-nucleoside reverse transcriptase inhibitors (e.g., rilpivirine and doravirine), pharmacokinetic enhancers (i.e., ritonavir, cobicistat), and some integrase strand transfer inhibitors (i.e., elvitegravir, bictegravir) |
| Azithromycin | Protease inhibitors (e.g., atazanavir) and cobicistat may increase concentrations of CFTR modulators. |
| Inhaled beta-2 adrenergic receptor agonists (e.g., salbutamol) | Efavirenz may decrease concentrations of CFTR modulators. |
| Inhaled anticholinergics (e.g., ipratropium, tiotropium) | Supratherapeutic doses of rilpivirine are associated with prolongation of QTc, but this is unlikely to occur with coadministration with azithromycin. |
| Theophylline | No interaction expected |

The importance of early diagnosis and treatment of HIV has been demonstrated, resulting in improved patient outcomes [6,7]. The patient's hospitalization, totaling over 3 months, may have been averted or ameliorated by earlier HIV screening. As advances in care and treatment continue to extend life expectancy in both CF and HIV, providers may see more patients with this dual diagnosis. Clinicians providing care for CF patients should screen for not only CF-related co-morbidities (e.g., diabetes, bone, liver disease, anxiety and depression) [8–11], but also for conditions, such as HIV, found in the general population.

The outcomes for patients with this dual diagnosis are unknown, but each condition is likely to impact the disease course of the other. HIV suppresses CFTR biogenesis and function and bronchial epithelial cell differentiation [12,13]. This may partly explain why PWH are at increased risk of lung infections, fibrosis and other pulmonary comorbidities [14,15]. Increased HIV viral loads have been associated with fibrotic changes in the lung [16]. However, even in patients with controlled HIV, increased risk of pulmonary comorbidities remains [17].

A dual diagnosis of CF and HIV presents a number of management challenges, which may include drug interactions (shown in Table 1), altered drug absorption and pharmacokinetics [18–20], medication adherence, and potential macrolide resistance in mycobacterial infection. Rates of depression are higher in both patient populations [21–23] and may negatively impact outcomes. In addition, CF patients may require lung transplantation. In most transplant centers HIV infection is still considered a contraindication to lung transplantation. However, a successful double lung transplant in a patient with CF and HIV was reported by Bertani et al. [3]. In 2013 the HIV Organ Policy Equity act was passed, which allows for transplantation of organs from donors with HIV to PWH as part of a clinical trial. Lung transplantation may be considered routinely in the future for this population. Additional care will need to be taken to evaluate the complications posed by drug interactions between CF, HIV and transplant medications.

In conclusion, our case involving a patient with known CF and a new diagnosis of advanced HIV illustrates that: 1) providers caring for patients with one serious chronic medical condition may be susceptible to anchor bias, attributing new findings to the known condition before considering alternative explanations, resulting delayed diagnoses; and 2) patients with CF are living longer and HIV screening should be incorporated into their routine care.

Author contributions

All authors meet the four ICMJE criteria for authorship.

Declarations

- Written informed consent was obtained from the patient for publication of this case report and is available from the corresponding author;
- This research did not receive any grant funding support from public, commercial, or not-for profit sectors;
- This manuscript has not been published previously, nor is it under consideration for publication elsewhere.
- The manuscript has been approved by all authors
Declaration of competing interest

Bernadette Jakeman, PharmD, serves as a consultant for Wolters-Kluwer. Keenan Ryan PharmD, serves as a speaker for Surgent Pharmon. The other authors of this manuscript have no conflicts of interest to declare, including employment, consultancies, stock ownership and options, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding received or pending.

Acknowledgements

None.

References

[1] Cystic Fibrosis Foundation, Patient Registry Annual Report, 2018. Available from. https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-PatientRegistry-Annual-Data-Report.pdf. (Accessed 22 November 2020).

[2] H.X. Hoyer, H. Schmid, F. Gamarra, R. Fischer, M. Woerther, Cystic fibrosis diagnosed in a 38-year-old man with long standing HIV infection, Clin. Infect. Dis. 39 (2004) 438–439.

[3] A. Bertani, P. Grossi, P. Vitulo, G. D’Ancona, A. Arcadipane, et al., Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis, Am. J. Transplant. 9 (9) (2009 Sep) 2190–2196, https://doi.org/10.1111/j.1600-6143.2009.02779.x.

[4] Centers for Disease Control and Prevention, Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings, MMWR (Morb. Mortal. Wkly. Rep.) 55 (RR15) (2006) 1–17.

[5] European Centre for Disease Prevention and Control, Public Health Guidance on HIV, Hepatitis B and C Testing in the EU/EEA: an Integrated Approach, 2018, Available from. https://www.ecdc.europa.eu/sites/default/files/documents/hiv-hep-testing-guidance_0.pdf. (Accessed 2 December 2020).

[6] M. May, M. Gompels, V. Delpech, K. Porter, F. Post, M. Johnson, et al., Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UCHC) Study, BMJ 343 (2001 Oct) d6016, https://doi.org/10.1136/bmj.d6016.

[7] M.M. Kitahata, S.J. Gange, A.G. Abraham, B. Merriman, M.S. Saag, A.C. Justice, et al., Effect of early versus deferred antiretroviral therapy for HIV on survival, N. Engl. J. Med. 360 (2009 Apr) 1815–1826, https://doi.org/10.1056/NEJMoa0807252.

[8] A. Moran, C. Brunzell, R.C. Cohen, M. Katz, B.C. Marshall, G. Onady, et al., Clinical care guidelines for cystic fibrosis-related diabetes, Diabetes Care 33 (12) (2010 Dec) 2697–2708, https://doi.org/10.2337/dc10-1768.

[9] R.M. Aris, P.A. Merkel, L.K. Bachrach, D.S. Borowitz, M.P. Boyle, S.L. Elkin, et al., Guide to bone health and disease in cystic fibrosis, J. Clin. Endocrinol. Metab. 90 (3) (2005 Mar) 1888–1896, https://doi.org/10.1210/jc.2004-1629.

[10] R.J. Sokol, P.R. Durie, Cystic fibrosis foundation hepatobiliary disease consensus group, Recommendations for management of liver and biliary tract disease in cystic fibrosis, J. Pediatr. Gastroenterol. Nutr. 28 (Suppl 1) (1999) S1–S13, https://doi.org/10.1097/00005176-199900010-00001.

[11] A.L. Quittner, J. Abbott, A.M. Georgiopoulou, L. Goldbeck, B. Smith, S.E. Hempstead, et al., International committee on mental health in cystic fibrosis: cystic fibrosis foundation and European cystic fibrosis society consensus statements for screening and treating depression and anxiety, Thorax 71 (1) (2016) 26–34, https://doi.org/10.1136/thoraxjnl-2015-207488.

[12] S. Chinnapaian, R. Dutta, J. Bala, T. Parira, M. Agudeo, M. Nair, et al., Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function, Sci. Rep. 8 (2018 May) 7984, https://doi.org/10.1038/s41598-018-26905-x.

[13] S. Chinnapaian, T. Parira, R. Dutta, M. Agudeo, A. Morris, M. Nair, et al., HIV infects bronchial epithelium and suppresses components of the mucociliary clearance apparatus, PLoS One 12 (2017 Jan) e0169161, https://doi.org/10.1371/journal.pone.0169161.

[14] K. Crothers, L. Huang, J.L. Goulet, M. Bidwell Goetz, S.T. Brown, M.C. Rodriguez-Barradas, et al., HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era, Am. J. Respir. Crit. Care Med. 183 (2011 Feb) 388–395, https://doi.org/10.1164/rccm.201006-0836OC.

[15] K. Crothers, A.A. Butt, C.L. Gilbert, M.C. Rodriguez-Barradas, S. Crystal, A.C. Justice, et al., Increased COPD among HIV-positive compared to HIV-negative veterans, Chest 130 (5) (2006 Nov) 1326–1333, https://doi.org/10.1378/chest.130.5.1326.

[16] J.K. Leader, K. Crothers, L. Huang, M.A. King, A. Morris, B.W. Thompson, et al., Risk factors associated with quantitative evidence of lung emphysema and fibrosis in an HIV-infected cohort, J. Acquir. Immune Defic. Syndr. 71 (2017 Apr) 420–427, https://doi.org/10.1097/QAI.0000000000001894.

[17] M.R. Gingo, A. Morris, Pathogenesis of HIV and the lung, Curr. HIV AIDS Rep. 10 (1) (2013 Mar) 42–50, https://doi.org/10.1007/s11990-012-0140-x.

[18] M.R. Struyvenberg, C.R. Martin, S.D. Freedman, Practical guide to exocrine pancreatic insufficiency – breaking the myths, BMC Med. 15 (1) (2017 Feb) 29, https://doi.org/10.1186/s12916-017-0783-y.

[19] A.E. Oleen, A. Brokjaer, I.W. Fisher, I.M. Larsen, Pharmacological challenges in chronic pancreatitis, World J. Gastroenterol. 19 (42) (2013 Nov) 7302–7307, https://doi.org/10.3748/wjg.v19.i42.7302.

[20] D.J. Touw, Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis, Pharm. World Sci. 20 (4) (1998 Aug) 149–160, https://doi.org/10.1023/a:1008634911114.

[21] J.A. Ciesla, J.E. Roberts, Meta-analysis of the relationship between HIV infection and risk for depressive disorders, Am J Psychiatry 158 (5) (2001 May) 725–730, https://doi.org/10.1176/appi.ajp.158.5.725.

[22] M. Orlando, M.A. Burnam, R. Beckman, S.C. Morton, A.S. London, E.G. Bing, et al., Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study, Int. J. Methods Psychiatr. Res. 11 (2) (2002) 75–82, https://doi.org/10.1002/mpr.125.

[23] A.L. Quittner, L. Goldbeck, J. Abbott, A. Duff, P. Lambrecht, A. Sole, et al., Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the International Depression Epidemiology Study across nine countries, Thorax 69 (4) (2014) 1090–1097, https://doi.org/10.1136/thoraxjnl-2014-205985.

[24] HIV Drug Interactions, University of Liverpool, in: https://www.hiv-druginteractions.org/, (Accessed 13 September 2021).

[25] Lexicomp®, in: http://online.lexi.com. (Accessed 13 September 2021).